HY015

HY015 is a preclinical-stage chimeric antigen receptor T-cell (CAR-T) therapy being developed by Juventas Cell Therapy (Juventas Bio) for the treatment of multiple myeloma. As an autologous cell therapy, it involves the genetic modification of a patient's T cells to express a receptor designed to recognize and eliminate malignant plasma cells. While the specific molecular target (such as BCMA or GPRC5D) has not been publicly disclosed by the sponsor in their primary pipeline documentation, HY015 is a key asset in Juventas's expanding hematological oncology portfolio, which also includes the approved CD19-targeted CAR-T therapy CNCT19.